CAMs as counter measures against infectious and inflammatory disease

Information

  • Research Project
  • 7574619
  • ApplicationId
    7574619
  • Core Project Number
    P01AT004986
  • Full Project Number
    1P01AT004986-01
  • Serial Number
    4986
  • FOA Number
    PAR-06-047
  • Sub Project Id
  • Project Start Date
    9/30/2008 - 15 years ago
  • Project End Date
    8/31/2013 - 10 years ago
  • Program Officer Name
    PONTZER, CAROL H
  • Budget Start Date
    9/30/2008 - 15 years ago
  • Budget End Date
    8/31/2009 - 14 years ago
  • Fiscal Year
    2008
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/29/2008 - 15 years ago
Organizations

CAMs as counter measures against infectious and inflammatory disease

[unreadable] DESCRIPTION (provided by applicant): CAMs are used for the prevention and treatment of infectious and inflammatory diseases, though for many of these CAMs, their true efficacy and the molecular basis for their purported benefits have not been defined and/or confirmed. We propose a new Center of Excellence for Research on CAMs (CERC) focused on the study of the mechanisms of action of diverse CAMs in models of pulmonary and intestinal infectious disease. Since in many instances the resulting inflammatory response associated with infection in the lung and intestinal track accounts for the actual pathology in the disease, we also intend to expand ongoing efforts in using CAMs to minimize inflammation induced tissue damage. The ultimate goal of this CERC is to provide critical insight into the mechanisms of action of select CAMs that can be used as countermeasures against emerging and select agents that infect the pulmonary and intestinal mucosa. This Center brings together scientists with expertise in bacterial and viral diseases of the lung and intestinal tract, study of CAM effects on innate leukocytes and epithelial cells, purification of defined agonists from crude plant extracts, use of probiotic CAMs, and use of rodent models of infectious and inflammatory disease to define specific mechanisms of action. This Center will also take advantage of new BSL-3 facilities to study the impact of CAMs on select agents. The CERC will initially be focused on three distinct projects, which will be supported by two Cores: Administrative (Core A) and Animal Model (Core B). The three Research Projects are: Project 1) CAMs that enhance ??T cell function, Project Leader, Mark Jutila, Ph.D.; Project 2) Anti-viral CAMs, Project Leader, Dr. Michele Hardy, Ph.D.; and Project 3) Anti-inflammatory microbial CAMs and arthritis, Project Leader, Dr. David Pascual, Ph.D. The Animal Models Core will serve as a unique and highly interactive resource, facilitating synergy and collaboration between the three research projects. [unreadable] [unreadable] PUBLIC HEALTH RELEVANCE: CAMs are widely used by the public to treat a variety of ailments, however, in many instances their true efficacy, safety and specific mechanisms of action are unknown. This proposed CERC provides a unique focus on mechanistic studies of CAMs that counter infectious and inflammatory disease. It directly addresses the goals of the NCCAM, and will provide important new information relevant to the use of CAMs. [unreadable] [unreadable]

IC Name
NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE
  • Activity
    P01
  • Administering IC
    AT
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    1200000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    213
  • Ed Inst. Type
  • Funding ICs
    NCCAM:1200000\
  • Funding Mechanism
  • Study Section
    ZAT1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MONTANA STATE UNIVERSITY (BOZEMAN)
  • Organization Department
    VETERINARY SCIENCES
  • Organization DUNS
  • Organization City
    BOZEMAN
  • Organization State
    MT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    59717
  • Organization District
    UNITED STATES